Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-BCMA/GPRC5D/CD3 trispecific antibody SIM0500

A humanized T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and human G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-BCMA/GPRC5D/CD3 trispecific antibody SIM0500 simultaneously targets and binds to BCMA and GPRC5D expressed on tumor cells, and CD3 expressed on T cells. The resulting cross-linkage activates and redirects CTLs to GPRC5D- and BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. GPRC5D is overexpressed on certain tumors, including multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.
Synonym:anti-GPRC5D/anti-BCMA/anti-CD3 trispecific antibody SIM0500
GPRC5D-BCMA-CD3 trispecific antibody SIM0500
GPRC5DxBCMAxCD3 trispecific antibody SIM0500
Code name:SIM 0500
SIM-0500
SIM0500
Search NCI's Drug Dictionary